Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free GANX Stock Alerts

Gain Therapeutics (GANX) Financials

Gain Therapeutics logo
$1.66 -0.02 (-1.19%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$1.66 +0.01 (+0.30%)
As of 07/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Gain Therapeutics

Annual Income Statements for Gain Therapeutics

This table shows Gain Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -3.58 -14 -18 -22 -20 -20
Consolidated Net Income / (Loss)		 -3.58 -14 -18 -22 -20 -20
Net Income / (Loss) Continuing Operations		 -3.58 -14 -18 -22 -20 -20
Total Pre-Tax Income 		-3.57 -14 -17 -22 -20 -19
Total Operating Income		 -3.48 -14 -18 -22 -20 -19
Total Gross Profit		 0.03 0.16 0.14 0.06 0.00 0.00
Total Revenue		 0.03 0.16 0.14 0.06 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 3.51 14 18 22 20 19
Selling, General & Admin Expense		 1.25 6.83 9.54 11 9.56 8.50
Research & Development Expense		 2.26 7.16 8.38 12 11 10
Total Other Income / (Expense), net		 -0.09 -0.06 0.28 0.06 0.48 -0.59
Interest & Investment Income		 - - - 0.49 0.36 0.24
Other Income / (Expense), net		 -0.10 -0.07 -0.10 -0.43 0.12 -0.83
Income Tax Expense		 0.01 0.00 0.09 0.08 0.54 0.86
Basic Earnings per Share		 ($1.33) ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Weighted Average Basic Shares Outstanding		 2.68M 10.17M 11.88M 13.01M 22.88M 32.97M
Diluted Earnings per Share		 ($1.33) ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Weighted Average Diluted Shares Outstanding		 2.68M 10.17M 11.88M 13.01M 22.88M 32.97M
Weighted Average Basic & Diluted Shares Outstanding		 - 11.88M 11.88M 16.22M 27.79M 42.24M

Quarterly Income Statements for Gain Therapeutics

This table shows Gain Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.72 -4.72 -4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61
Consolidated Net Income / (Loss)		 -4.72 -4.72 -4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61
Net Income / (Loss) Continuing Operations		 -4.72 -4.72 -4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61
Total Pre-Tax Income 		-4.70 -4.71 -3.99 -8.14 -4.47 -3.26 -4.43 -5.67 -4.74 -4.47 -5.43
Total Operating Income		 -4.89 -4.41 -4.38 -8.18 -4.46 -3.33 -4.37 -5.09 -4.79 -4.47 -5.35
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.89 4.41 4.38 8.18 4.46 3.33 4.37 5.09 4.79 4.47 5.35
Selling, General & Admin Expense		 2.52 2.03 1.87 3.75 1.84 2.11 2.11 2.33 1.94 2.12 2.59
Research & Development Expense		 2.37 2.37 2.51 4.44 2.62 1.22 2.26 2.76 2.85 2.35 2.76
Total Other Income / (Expense), net		 0.19 -0.30 0.38 0.04 -0.02 0.07 -0.06 -0.58 0.05 -0.00 -0.07
Interest & Investment Income		 - - 0.12 0.08 0.11 0.05 0.04 0.04 0.08 0.08 0.09
Other Income / (Expense), net		 0.08 -0.41 0.27 -0.04 -0.12 0.02 -0.10 -0.62 -0.03 -0.08 -0.17
Income Tax Expense		 0.02 0.01 0.02 0.00 0.01 0.50 0.10 0.14 0.55 0.07 0.18
Basic Earnings per Share		 ($0.37) ($0.29) ($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13)
Weighted Average Basic Shares Outstanding		 12.70M 13.01M 17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M
Diluted Earnings per Share		 ($0.37) ($0.29) ($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13)
Weighted Average Diluted Shares Outstanding		 12.70M 13.01M 17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M
Weighted Average Basic & Diluted Shares Outstanding		 12.91M 16.22M 18.05M 25.54M 26.53M 27.79M 29.56M 35.95M 36.10M 42.24M 42.65M

Annual Cash Flow Statements for Gain Therapeutics

This table details how cash moves in and out of Gain Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 7.19 29 -30 4.49 -1.41 10
Net Cash From Operating Activities		 -3.24 -12 -15 -19 -19 -18
Net Cash From Continuing Operating Activities		 -3.24 -12 -15 -19 -19 -18
Net Income / (Loss) Continuing Operations		 -3.58 -14 -18 -22 -20 -20
Consolidated Net Income / (Loss)		 -3.58 -14 -18 -22 -20 -20
Depreciation Expense		 0.01 0.02 0.06 0.08 0.08 0.09
Non-Cash Adjustments To Reconcile Net Income		 0.07 1.84 1.32 2.88 2.53 2.61
Changes in Operating Assets and Liabilities, net		 0.26 -0.31 1.45 0.44 -1.08 -1.01
Net Cash From Investing Activities		 -0.02 -0.09 -15 10 4.98 0.00
Net Cash From Continuing Investing Activities		 -0.02 -0.09 -15 10 4.98 0.00
Purchase of Property, Plant & Equipment		 -0.02 -0.09 -0.12 -0.02 -0.02 0.00
Sale and/or Maturity of Investments		 - 0.00 3.08 12 5.00 0.00
Net Cash From Financing Activities		 10 42 -0.08 13 13 28
Net Cash From Continuing Financing Activities		 10 42 -0.08 13 13 28
Repayment of Debt		 0.00 -0.02 -0.08 -0.09 -0.09 -0.10
Repurchase of Common Equity		 -0.47 -0.85 - 0.00 -0.28 -0.40
Issuance of Debt		 0.74 - 0.00 9.19 10 7.41
Issuance of Common Equity		 0.00 43 0.00 3.54 2.95 18
Other Financing Activities, net		 0.00 0.01 - 0.00 0.17 3.47
Effect of Exchange Rate Changes		 -0.04 0.10 -0.02 0.49 -0.53 0.47
Cash Income Taxes Paid		 - 0.00 0.00 0.13 0.09 0.05

Quarterly Cash Flow Statements for Gain Therapeutics

This table details how cash moves in and out of Gain Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.05 7.53 -1.16 6.30 -4.88 -1.67 -1.31 -2.37 2.11 12 -4.30
Net Cash From Operating Activities		 -3.97 -5.66 -3.59 -5.76 -6.08 -3.45 -3.82 -5.10 -4.93 -4.62 -4.73
Net Cash From Continuing Operating Activities		 -3.97 -5.66 -3.59 -5.76 -6.08 -3.45 -3.82 -5.10 -4.93 -4.62 -4.73
Net Income / (Loss) Continuing Operations		 -4.72 -4.72 -4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61
Consolidated Net Income / (Loss)		 -4.72 -4.72 -4.01 -8.14 -4.49 -3.77 -4.53 -5.81 -5.28 -4.54 -5.61
Depreciation Expense		 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.73 0.42 -0.04 1.29 0.28 1.01 0.53 1.15 0.44 0.52 0.63
Changes in Operating Assets and Liabilities, net		 0.01 -1.38 0.45 1.08 -1.89 -0.71 0.16 -0.46 -0.10 -0.63 0.23
Net Cash From Investing Activities		 1.93 3.14 3.02 2.00 -0.00 -0.04 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 1.93 3.14 3.02 2.00 -0.00 -0.04 0.00 - - - 0.00
Net Cash From Financing Activities		 0.13 9.56 -0.15 10 0.81 2.31 2.40 2.47 7.03 17 0.40
Net Cash From Continuing Financing Activities		 0.13 9.56 -0.15 10 0.81 2.31 2.40 2.47 7.03 17 0.40
Repayment of Debt		 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.03 -0.03
Issuance of Common Equity		 0.16 0.40 0.00 - 0.62 2.34 2.42 2.49 - 13 0.43
Other Financing Activities, net		 - - 0.16 0.01 0.00 -0.00 0.00 - 0.04 3.43 0.00
Effect of Exchange Rate Changes		 -0.14 0.48 -0.44 0.01 0.38 -0.48 0.11 0.26 0.01 0.10 0.02

Annual Balance Sheets for Gain Therapeutics

This table presents Gain Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 9.60 39 24 19 12 23
Total Current Assets		 8.99 38 21 18 12 22
Cash & Equivalents		 7.49 37 7.31 12 10 21
Prepaid Expenses		 0.20 0.73 0.85 0.74 0.95 1.22
Current Deferred & Refundable Income Taxes		 0.06 0.11 0.10 0.24 0.27 0.18
Plant, Property, & Equipment, net		 0.03 0.11 0.14 0.13 0.10 0.07
Total Noncurrent Assets		 0.59 1.16 2.86 0.70 0.42 0.51
Intangible Assets		 - 0.20 0.21 0.19 0.13 0.10
Other Noncurrent Operating Assets		 0.59 0.95 0.71 0.51 0.28 0.40
Total Liabilities & Shareholders' Equity		 9.60 39 24 19 12 23
Total Liabilities		 3.40 4.17 5.22 6.03 4.78 4.25
Total Current Liabilities		 2.11 2.55 4.13 4.95 3.91 3.35
Short-Term Debt		 0.02 0.10 0.11 0.12 0.11 0.10
Accounts Payable		 0.96 0.56 1.63 1.32 0.95 0.83
Other Current Liabilities		 0.89 1.62 2.34 2.39 2.60 2.43
Total Noncurrent Liabilities		 1.29 1.61 1.09 1.08 0.87 0.90
Long-Term Debt		 0.72 0.59 0.50 0.45 0.33 0.30
Noncurrent Employee Benefit Liabilities		 0.17 0.33 0.16 0.31 0.44 0.39
Other Noncurrent Operating Liabilities		 0.40 0.70 0.44 0.23 0.05 0.21
Total Equity & Noncontrolling Interests		 6.20 35 19 13 7.34 19
Total Preferred & Common Equity		 6.20 35 19 13 7.34 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 6.20 35 19 13 7.34 19
Common Stock		 13 56 57 73 89 119
Retained Earnings		 -3.46 -7.03 -21 -39 -61 -81
Accumulated Other Comprehensive Income / (Loss)		 -0.15 -0.09 0.04 0.25 -0.25 0.78
Other Equity Adjustments		 -3.58 -14 -18 -22 -20 -20

Quarterly Balance Sheets for Gain Therapeutics

This table presents Gain Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 14 15 19 14 12 9.83 11 19
Total Current Assets		 13 14 19 14 11 9.31 11 18
Cash & Equivalents		 4.27 11 17 12 9.07 6.69 8.81 17
Prepaid Expenses		 0.91 0.95 1.29 1.32 1.83 2.29 1.44 1.45
Current Deferred & Refundable Income Taxes		 0.10 0.25 0.31 0.37 0.25 0.32 0.27 0.23
Plant, Property, & Equipment, net		 0.13 0.11 0.12 0.12 0.10 0.10 0.09 0.05
Total Noncurrent Assets		 0.73 0.60 0.53 0.50 0.38 0.43 0.37 0.46
Intangible Assets		 0.19 0.17 0.16 0.16 0.13 0.13 0.11 0.09
Other Noncurrent Operating Assets		 0.54 0.43 0.38 0.35 0.25 0.30 0.25 0.37
Total Liabilities & Shareholders' Equity		 14 15 19 14 12 9.83 11 19
Total Liabilities		 6.77 5.94 7.41 5.46 5.84 6.14 5.06 4.73
Total Current Liabilities		 5.76 5.00 6.52 4.59 5.03 5.20 4.17 3.89
Short-Term Debt		 0.11 0.11 0.11 0.12 0.11 0.13 0.13 0.10
Accounts Payable		 1.38 1.41 2.05 1.10 2.15 2.71 1.58 1.52
Other Current Liabilities		 2.92 2.57 3.66 2.67 2.55 2.34 2.46 2.27
Total Noncurrent Liabilities		 1.00 0.93 0.89 0.86 0.82 0.94 0.89 0.84
Long-Term Debt		 0.43 0.40 0.38 0.38 0.31 0.33 0.30 0.27
Noncurrent Employee Benefit Liabilities		 0.16 0.29 0.30 0.32 0.47 0.52 0.53 0.39
Other Noncurrent Operating Liabilities		 0.26 0.18 0.13 0.10 0.03 0.09 0.07 0.18
Total Equity & Noncontrolling Interests		 7.33 8.64 12 8.91 5.78 3.70 5.91 14
Total Preferred & Common Equity		 7.33 8.64 12 8.91 5.78 3.70 5.91 14
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 7.33 8.64 12 8.91 5.78 3.70 5.91 14
Common Stock		 63 73 85 86 92 95 102 120
Retained Earnings		 -39 -61 -61 -61 -81 -81 -81 -101
Accumulated Other Comprehensive Income / (Loss)		 0.09 0.02 0.01 0.24 -0.12 0.58 0.56 1.00
Other Equity Adjustments		 -18 -4.01 -12 -17 -4.53 -10 -16 -5.61

Annual Metrics And Ratios for Gain Therapeutics

This table displays calculated financial ratios and metrics derived from Gain Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 11,879,743.00 11,883,368.00 12,910,342.00 26,525,068.00 36,097,536.00
DEI Adjusted Shares Outstanding		 0.00 11,879,743.00 11,883,368.00 12,910,342.00 26,525,068.00 36,097,536.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.17 -1.48 -1.72 -0.77 -0.56
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 471.29% -15.08% -60.62% -100.00% 0.00%
EBITDA Growth		 0.00% -289.30% -28.27% -26.90% 10.85% 3.46%
EBIT Growth		 0.00% -288.68% -28.59% -26.91% 10.81% 3.40%
NOPAT Growth		 0.00% -297.37% -28.58% -25.18% 8.55% 8.06%
Net Income Growth		 0.00% -288.26% -26.64% -26.59% 8.34% 1.23%
EPS Growth		 0.00% -3.01% -8.03% -15.54% 47.95% 31.46%
Operating Cash Flow Growth		 0.00% -281.63% -18.81% -28.41% -0.04% 2.16%
Free Cash Flow Firm Growth		 0.00% 0.00% -26.38% -29.51% -5.24% 9.50%
Invested Capital Growth		 0.00% -142.24% -89.73% -40.48% 28.53% 28.22%
Revenue Q/Q Growth		 0.00% 59.29% -33.49% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -12.67% -9.33% -0.22% 6.92% -6.74%
EBIT Q/Q Growth		 0.00% -12.68% -9.37% -0.25% 6.90% -6.75%
NOPAT Q/Q Growth		 0.00% -13.02% -8.23% 0.69% 5.02% -6.46%
Net Income Q/Q Growth		 0.00% -12.69% -9.01% -0.22% 4.47% -3.97%
EPS Q/Q Growth		 0.00% 19.88% -16.54% 5.52% 19.09% -5.17%
Operating Cash Flow Q/Q Growth		 0.00% -29.79% 1.62% -10.26% 10.46% -6.73%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 5.16% -5.83% 8.53% -10.89%
Invested Capital Q/Q Growth		 0.00% 49.81% -8.27% 16.28% 1.43% 24.32%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -12,348.40% -8,414.61% -12,710.87% -40,954.88% 0.00% 0.00%
Operating Margin		 -12,047.54% -8,379.80% -12,688.10% -40,328.26% 0.00% 0.00%
EBIT Margin		 -12,381.61% -8,424.00% -12,756.67% -41,106.34% 0.00% 0.00%
Profit (Net Income) Margin		 -12,387.67% -8,418.86% -12,555.13% -40,354.33% 0.00% 0.00%
Tax Burden Percent		 100.15% 100.03% 100.53% 100.36% 102.70% 104.46%
Interest Burden Percent		 99.90% 99.91% 97.90% 97.82% 98.23% 98.75%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -57.69% -67.73% -65.52% -141.57% -204.95% -155.66%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -37.23% -57.21% -56.66% -106.22% 0.00% 0.00%
Return on Assets (ROA)		 -37.25% -57.18% -55.77% -104.28% 0.00% 0.00%
Return on Common Equity (ROCE)		 -57.68% -67.73% -65.52% -141.57% -204.95% -155.66%
Return on Equity Simple (ROE_SIMPLE)		 -57.69% -39.90% -93.17% -177.03% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.44 -9.68 -12 -16 -14 -13
NOPAT Margin		 -8,433.28% -5,865.86% -8,881.67% -28,229.78% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -16.88% -19.61% -17.85% -35.49% -47.11% -46.50%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -118.49% -183.15% -69.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 4,325.08% 4,137.69% 6,808.94% 19,550.02% 0.00% 0.00%
R&D to Revenue		 7,822.46% 4,342.11% 5,979.17% 20,878.24% 0.00% 0.00%
Operating Expenses to Revenue		 12,147.54% 8,479.80% 12,788.10% 40,428.26% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.58 -14 -18 -23 -20 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.57 -14 -18 -23 -20 -19
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 6.45 1.85 1.97 3.35 7.81 6.26
Price to Tangible Book Value (P/TBV)		 6.45 1.86 1.99 3.40 7.95 6.30
Price to Revenue (P/Rev)		 1,384.99 390.97 265.47 763.90 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,150.74 171.65 112.19 469.83 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.12 0.02 0.03 0.05 0.06 0.02
Long-Term Debt to Equity		 0.12 0.02 0.03 0.04 0.04 0.02
Financial Leverage		 -1.09 -1.05 -1.07 -1.20 -1.31 -1.17
Leverage Ratio		 1.55 1.18 1.17 1.36 1.54 1.35
Compound Leverage Factor		 1.55 1.18 1.15 1.33 1.52 1.33
Debt to Total Capital		 10.64% 1.96% 3.10% 4.32% 5.64% 2.11%
Short-Term Debt to Total Capital		 0.33% 0.29% 0.56% 0.90% 1.42% 0.53%
Long-Term Debt to Total Capital		 10.31% 1.66% 2.54% 3.42% 4.22% 1.58%
Preferred Equity to Total Capital		 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 89.36% 98.04% 96.90% 95.68% 94.36% 97.89%
Debt to EBITDA		 -0.21 -0.05 -0.03 -0.03 -0.02 -0.02
Net Debt to EBITDA		 1.90 2.61 1.21 0.72 0.49 1.05
Long-Term Debt to EBITDA		 -0.20 -0.04 -0.03 -0.02 -0.02 -0.02
Debt to NOPAT		 -0.30 -0.07 -0.05 -0.04 -0.03 -0.03
Net Debt to NOPAT		 2.78 3.74 1.73 1.04 0.70 1.56
Long-Term Debt to NOPAT		 -0.29 -0.06 -0.04 -0.03 -0.02 -0.02
Altman Z-Score		 6.18 8.94 1.46 -1.90 -4.58 9.58
Noncontrolling Interest Sharing Ratio		 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 4.25 14.78 5.11 3.59 2.97 6.63
Quick Ratio		 3.55 14.45 4.88 3.39 2.66 6.22
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.87 -11 -15 -15 -14
Operating Cash Flow to CapEx		 -15,558.61% -13,125.37% -12,351.21% -122,840.69% -83,909.78% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 3.38 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.97 2.43 1.12 0.41 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 108.03 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 108.03 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.57 -1.37 -2.60 -3.65 -2.61 -1.87
Invested Capital Turnover		 -0.05 -0.17 -0.07 -0.02 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.80 -1.23 -1.05 1.04 0.74
Enterprise Value (EV)		 33 28 16 26 47 96
Market Capitalization		 40 65 37 42 57 116
Book Value per Share		 $2.31 $2.93 $1.59 $0.97 $0.28 $0.51
Tangible Book Value per Share		 $2.31 $2.91 $1.57 $0.96 $0.27 $0.51
Total Capital		 6.94 36 19 13 7.78 19
Total Debt		 0.74 0.69 0.60 0.57 0.44 0.40
Total Long-Term Debt		 0.72 0.59 0.50 0.45 0.33 0.30
Net Debt		 -6.77 -36 -21 -16 -9.95 -20
Capital Expenditures (CapEx)		 0.02 0.09 0.12 0.02 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.61 -1.61 -3.06 -3.85 -2.58 -1.85
Debt-free Net Working Capital (DFNWC)		 6.90 35 17 13 7.80 19
Net Working Capital (NWC)		 6.87 35 17 13 7.69 19
Net Nonoperating Expense (NNE)		 1.14 4.21 5.15 6.69 6.17 7.06
Net Nonoperating Obligations (NNO)		 -6.77 -36 -21 -16 -9.95 -20
Total Depreciation and Amortization (D&A)		 0.01 0.02 0.06 0.08 0.08 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -2,107.47% -974.19% -2,187.16% -6,971.63% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 23,875.98% 21,378.55% 12,186.44% 23,464.49% 0.00% 0.00%
Net Working Capital to Revenue		 23,797.64% 21,315.62% 12,109.26% 23,249.20% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 10.17M 11.88M 13.01M 22.88M 32.97M
Adjusted Diluted Earnings per Share		 $0.00 ($1.37) ($1.48) ($1.71) ($0.89) ($0.61)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 10.17M 11.88M 13.01M 22.88M 32.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 11.88M 11.88M 16.22M 27.79M 42.24M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.44 -9.68 -12 -16 -14 -13
Normalized NOPAT Margin		 -8,433.28% -5,865.86% -8,881.67% -28,229.78% 0.00% 0.00%
Pre Tax Income Margin		 -12,369.02% -8,416.43% -12,488.77% -40,210.67% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -13.16% -6.14% 0.00% 0.00% -1.38% -1.96%

Quarterly Metrics And Ratios for Gain Therapeutics

This table displays calculated financial ratios and metrics derived from Gain Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 12,699,422.00 12,910,342.00 16,219,709.00 18,051,979.00 25,535,460.00 26,525,068.00 27,786,952.00 29,557,640.00 35,948,606.00 36,097,536.00 42,241,947.00
DEI Adjusted Shares Outstanding		 12,699,422.00 12,910,342.00 16,219,709.00 18,051,979.00 25,535,460.00 26,525,068.00 27,786,952.00 29,557,640.00 35,948,606.00 36,097,536.00 42,241,947.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.37 -0.37 -0.25 -0.45 -0.18 -0.14 -0.16 -0.20 -0.15 -0.13 -0.13
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -1.98% -1.06% 22.16% -5.59% 4.68% 31.26% -8.81% 30.68% -5.09% -37.30% -23.56%
EBIT Growth		 -2.02% -1.17% 22.06% -5.58% 4.64% 31.16% -8.77% 30.58% -5.09% -37.26% -23.46%
NOPAT Growth		 -2.82% 3.38% 16.29% -5.84% 8.72% 24.42% 0.19% 37.80% -7.33% -34.07% -22.52%
Net Income Growth		 -3.51% -1.06% 21.86% -5.92% 4.93% 20.23% -12.85% 28.66% -17.81% -20.42% -23.81%
EPS Growth		 2.63% 25.64% 48.84% 32.26% 54.05% 72.41% 27.27% 54.76% 11.76% -37.50% 18.75%
Operating Cash Flow Growth		 -20.60% -44.97% 14.96% -14.64% -53.18% 38.97% -6.55% 11.42% 18.92% -33.69% -23.71%
Free Cash Flow Firm Growth		 60.03% -3.52% -7.57% -131.67% -230.95% -65.84% -40.86% -1.73% 27.13% -14.51% -20.10%
Invested Capital Growth		 -81.67% -40.48% -14.07% -3.17% 39.29% 28.53% 18.46% 45.41% 6.51% 28.22% 24.59%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 38.46% -0.21% 14.67% -100.68% 44.45% 27.74% -35.07% -27.84% 15.78% 5.59% -21.56%
EBIT Q/Q Growth		 38.36% -0.27% 14.66% -100.17% 44.32% 27.61% -34.83% -27.75% 15.71% 5.45% -21.27%
NOPAT Q/Q Growth		 36.81% 9.78% 0.67% -86.92% 45.51% 25.29% -31.17% -16.48% 5.97% 6.68% -19.87%
Net Income Q/Q Growth		 38.63% -0.12% 15.03% -102.86% 44.91% 15.99% -20.22% -28.23% 9.03% 14.13% -23.61%
EPS Q/Q Growth		 40.32% 21.62% 24.14% -90.91% 59.52% 52.94% -100.00% -18.75% 21.05% 26.67% -18.18%
Operating Cash Flow Q/Q Growth		 21.00% -42.70% 36.64% -60.50% -5.56% 43.14% -10.62% -33.43% 3.38% 6.25% -2.36%
Free Cash Flow Firm Q/Q Growth		 39.42% -39.25% -29.40% -112.24% 13.46% 30.22% -9.90% -53.28% 38.00% -9.65% -15.26%
Invested Capital Q/Q Growth		 3.63% 16.28% 3.78% -32.88% 43.29% 1.43% -9.78% 11.04% 2.87% 24.32% -15.32%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.46% 100.31% 100.50% 100.01% 100.25% 115.47% 102.27% 102.49% 111.60% 101.57% 103.37%
Interest Burden Percent		 97.79% 97.79% 97.19% 98.97% 97.70% 98.44% 99.10% 99.25% 98.38% 98.17% 98.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -148.15% -141.57% -177.83% -188.83% -263.14% -204.95% -290.21% -240.21% -261.72% -155.66% -214.69%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -148.15% -141.57% -177.83% -188.83% -263.14% -204.95% -290.21% -240.21% -261.72% -155.66% -214.69%
Return on Equity Simple (ROE_SIMPLE)		 -303.08% 0.00% -244.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.42 -3.09 -3.06 -5.73 -3.12 -2.33 -3.06 -3.56 -3.35 -3.13 -3.75
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -7.07% -8.69% -6.26% -15.06% -11.74% -10.98% -14.15% -19.80% -19.40% -9.29% -15.01%
Return On Investment Capital (ROIC_SIMPLE)		 - -23.47% -33.49% -46.68% -33.19% -29.98% -49.27% -85.90% -52.89% -16.48% -26.06%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.80 -4.82 -4.11 -8.23 -4.58 -3.32 -4.47 -5.71 -4.81 -4.55 -5.52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.78 -4.79 -4.09 -8.21 -4.56 -3.29 -4.45 -5.69 -4.79 -4.52 -5.50
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.68 3.35 7.08 1.96 5.10 7.81 9.18 14.39 10.77 6.26 5.85
Price to Tangible Book Value (P/TBV)		 5.83 3.40 7.22 1.99 5.19 7.95 9.39 14.91 10.98 6.30 5.89
Price to Revenue (P/Rev)		 754.88 763.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 543.05 469.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.07 0.05 0.06 0.04 0.06 0.06 0.07 0.12 0.07 0.02 0.03
Long-Term Debt to Equity		 0.06 0.04 0.05 0.03 0.04 0.04 0.05 0.09 0.05 0.02 0.02
Financial Leverage		 -1.23 -1.20 -1.28 -1.40 -1.43 -1.31 -1.44 -1.47 -1.35 -1.17 -1.25
Leverage Ratio		 1.41 1.36 1.51 1.64 1.75 1.54 1.82 1.88 1.71 1.35 1.53
Compound Leverage Factor		 1.38 1.33 1.47 1.62 1.71 1.52 1.80 1.86 1.68 1.32 1.51
Debt to Total Capital		 6.91% 4.32% 5.55% 3.96% 5.26% 5.64% 6.89% 10.89% 6.70% 2.11% 2.60%
Short-Term Debt to Total Capital		 1.39% 0.90% 1.21% 0.91% 1.26% 1.42% 1.82% 3.04% 1.98% 0.53% 0.70%
Long-Term Debt to Total Capital		 5.52% 3.42% 4.34% 3.06% 4.00% 4.22% 5.07% 7.84% 4.72% 1.58% 1.90%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 93.09% 95.68% 94.45% 96.04% 94.74% 94.36% 93.11% 89.11% 93.30% 97.89% 97.40%
Debt to EBITDA		 -0.02 -0.03 -0.02 -0.02 -0.02 -0.02 -0.02 -0.03 -0.02 -0.02 -0.02
Net Debt to EBITDA		 0.52 0.72 0.57 0.75 0.53 0.49 0.42 0.35 0.46 1.05 0.79
Long-Term Debt to EBITDA		 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.01
Debt to NOPAT		 -0.03 -0.04 -0.03 -0.03 -0.03 -0.03 -0.03 -0.04 -0.03 -0.03 -0.03
Net Debt to NOPAT		 0.75 1.04 0.81 1.08 0.77 0.70 0.61 0.52 0.68 1.56 1.17
Long-Term Debt to NOPAT		 -0.03 -0.03 -0.03 -0.02 -0.03 -0.02 -0.02 -0.03 -0.02 -0.02 -0.02
Altman Z-Score		 -0.62 1.27 0.14 -3.23 -1.21 0.03 -4.97 -7.77 -3.57 11.75 2.77
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.30 3.59 2.77 2.84 2.99 2.97 2.22 1.79 2.52 6.63 4.69
Quick Ratio		 2.12 3.39 2.53 2.60 2.62 2.66 1.80 1.29 2.11 6.22 4.26
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.46 -2.03 -2.63 -5.58 -4.83 -3.37 -3.71 -5.68 -3.52 -3.86 -4.45
Operating Cash Flow to CapEx		 -610,263.85% -29,791,468.42% 0.00% 0.00% -607,620,500.00% -365,569.95% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.42 0.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.36 -3.65 -3.51 -4.67 -2.65 -2.61 -2.86 -2.55 -2.47 -1.87 -2.16
Invested Capital Turnover		 -0.02 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.96 -1.05 -0.43 -0.14 1.71 1.04 0.65 2.12 0.17 0.74 0.70
Enterprise Value (EV)		 30 26 49 6.66 34 47 44 47 55 96 66
Market Capitalization		 42 42 61 23 45 57 53 53 64 116 82
Book Value per Share		 $0.58 $0.97 $0.53 $0.65 $0.35 $0.28 $0.21 $0.13 $0.16 $0.51 $0.33
Tangible Book Value per Share		 $0.56 $0.96 $0.52 $0.64 $0.34 $0.27 $0.20 $0.12 $0.16 $0.51 $0.33
Total Capital		 7.87 13 9.15 12 9.40 7.78 6.21 4.15 6.33 19 14
Total Debt		 0.54 0.57 0.51 0.49 0.49 0.44 0.43 0.45 0.42 0.40 0.37
Total Long-Term Debt		 0.43 0.45 0.40 0.38 0.38 0.33 0.31 0.33 0.30 0.30 0.27
Net Debt		 -12 -16 -12 -16 -12 -9.95 -8.64 -6.24 -8.38 -20 -16
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.65 -3.85 -3.69 -4.81 -2.78 -2.58 -2.83 -2.46 -2.34 -1.85 -2.10
Debt-free Net Working Capital (DFNWC)		 7.59 13 8.97 12 9.26 7.80 6.24 4.24 6.47 19 14
Net Working Capital (NWC)		 7.48 13 8.86 12 9.15 7.69 6.12 4.11 6.35 19 14
Net Nonoperating Expense (NNE)		 1.30 1.64 0.95 2.42 1.36 1.44 1.47 2.25 1.93 1.41 1.86
Net Nonoperating Obligations (NNO)		 -12 -16 -12 -16 -12 -9.95 -8.64 -6.24 -8.38 -20 -16
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 -8,418.64% -6,971.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 13,750.28% 23,464.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 13,552.24% 23,249.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.29) ($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 12.70M 13.01M 17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M
Adjusted Diluted Earnings per Share		 ($0.37) ($0.29) ($0.22) ($0.42) ($0.17) ($0.08) ($0.16) ($0.19) ($0.15) ($0.11) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 12.70M 13.01M 17.98M 19.22M 26.53M 22.88M 28.69M 30.34M 35.00M 32.97M 42.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.91M 16.22M 18.05M 25.54M 26.53M 27.79M 29.56M 35.95M 36.10M 42.24M 42.65M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.42 -3.09 -3.06 -5.73 -3.12 -2.33 -3.06 -3.56 -3.35 -3.13 -3.75
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -1.33% 0.00% -1.31% -1.38% 0.00% 0.00% -2.04% -1.96% 0.00%

Financials Breakdown Chart

Gain Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Gain Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Gain Therapeutics' net income appears to be on an upward trend, with a most recent value of -$20.16 million in 2025, rising from -$3.58 million in 2020. The previous period was -$20.41 million in 2024. View Gain Therapeutics' forecast to see where analysts expect Gain Therapeutics to go next.

Gain Therapeutics' total operating income in 2025 was -$18.71 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $18.71 million

Over the last 5 years, Gain Therapeutics' total revenue changed from $28.88 thousand in 2020 to $0.00 in 2025, a change of -100.0%.

Gain Therapeutics' total liabilities were at $4.25 million at the end of 2025, a 11.1% decrease from 2024, and a 25.0% increase since 2020.

In the past 5 years, Gain Therapeutics' cash and equivalents has ranged from $7.31 million in 2022 to $36.88 million in 2021, and is currently $20.84 million as of their latest financial filing in 2025.

Over the last 5 years, Gain Therapeutics' book value per share changed from 2.31 in 2020 to 0.51 in 2025, a change of -77.8%.


Related Companies

Financial statements for NASDAQ:GANX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel